adjuvanted low-dose quadrivalent VLP influenza vaccine

**Adjuvanted low-dose quadrivalent VLP influenza vaccine** was a Medicago-developed, plant-derived seasonal influenza vaccine candidate evaluated in a randomized Phase II study in adults aged 50 years and older. It contained recombinant influenza hemagglutinin proteins assembled into virus-like particles produced through transient expression in *Nicotiana benthamiana* plants, with a low antigen dose administered with the aluminum hydroxide adjuvant Alhydrogel. The quadrivalent formulation was designed to induce protective immune responses against two influenza A and two influenza B vaccine strains. Medicago subsequently ceased operations and development of its product portfolio was discontinued.

Other names

adjuvanted low dose quadrivalent VLP vaccine-Medicago-Influenzaplant-derived seasonal quadrivalent VLP influenza vaccine with Alhydrogel